Ansa Biotechnologies has secured $54.4 million in Series B financing, led by Cerberus Ventures. The funding will enable the company to scale its DNA synthesis services to meet increasing demand.

Oct 01, 2025•2 months ago

Amount Raised

$54.4 Million

Round Type

series b

EmeryvilleBiotechnology

Investors

Black Opal VenturesAim13Fall Line CapitalAltitude Life Science VenturesBlue Water Life Science AdvisorsCerberus Ventures

Description

Ansa Biotechnologies has closed $45.2 million and secured commitments for an additional $9.2 million in an oversubscribed Series B round led by Cerberus Ventures. This funding will allow Ansa to expand its manufacturing capacity and enhance customer experience. New board members from Cerberus Ventures and Fall Line Capital will aid Ansa's strategic goals. The investment supports the company's mission to redefine DNA synthesis standards.

Company Information

Company

Ansa Biotechnologies

Location

1198 65th St, Suite 250

Emeryville, California, United States

About

Ansa Biotechnologies is redefining DNA synthesis with a bold commitment to quality, customer satisfaction, and success. The Ansa On-Time Guarantee is simple and straightforward: your complete order on time or it’s free. This unprecedented level of service reliability and predictability is made possible by Ansa’s dedicated team of experts and proprietary enzymatic synthesis platform, which can rapidly and accurately produce even the highly complex DNA elements that stymie legacy approaches. Products are delivered as sequence-perfect clonal DNA or sequence-verified linear double-stranded DNA fragments. Headquartered in Emeryville, Calif., Ansa is empowering a global community of scientists to accelerate breakthroughs in healthcare, life sciences, and other industries powered by synthetic DNA.

Related People

3 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends